

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Qyuns Therapeutics Co., Ltd.
江蘇荃信生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2509)

- (1) ANNUAL RESULTS ANNOUNCEMENT
FOR THE YEAR ENDED DECEMBER 31, 2025;**
- (2) PROPOSED CHANGE IN USE OF PROCEEDS;**
- (3) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION,
RULES OF PROCEDURES FOR
THE GENERAL MEETING OF SHAREHOLDERS AND
RULES OF PROCEDURES FOR THE BOARD OF DIRECTORS;
AND**
- (4) PROPOSED ADOPTION OF THE 2026 SHARE INCENTIVE SCHEME**

ANNUAL RESULTS

The Board of the Company is pleased to announce the audited consolidated results of the Group for the Reporting Period, together with the audited comparative figures for the year ended December 31, 2024. The consolidated financial statements of the Group for the Reporting Period have been reviewed by the Audit Committee.

FINANCIAL HIGHLIGHTS

Operating Results	For the year ended December 31,	
	2025	2024
	RMB'000	RMB'000
Revenue	806,961	158,793
Cost of sales	(92,549)	(66,600)
Gross profit	714,412	92,193
Research and development expenses	(253,172)	(334,277)
Distribution and selling expenses	(30,588)	(926)
Profit/(Loss) for the year	307,444	(349,687)
Earnings/(Loss) per share – Basic and diluted (<i>in RMB</i>)	1.41	(1.53)
Adjusted profit/(loss) for the year (as illustrated under “ Non-IFRS Measures ”)	356,197	(274,227)
Financial Position	As of December 31,	
	2025	2024
	RMB'000	RMB'000
Cash and cash equivalents, time deposits and financial assets measured at fair value through profit or loss (FVPL)	1,041,968	556,127
Equity investment designated at FVOCI	134,864	–
Total non-current assets	483,658	367,152
Total current assets	1,116,668	616,725
Total non-current liabilities	417,487	332,666
Total current liabilities	503,743	430,161
Net current assets	612,925	186,564
Total equity	679,096	221,050

Revenue

For the year ended December 31, 2025, the Group's revenue increased by RMB648.2 million from RMB158.8 million in 2024 to RMB807.0 million, which mainly derived from (i) increase of licensing-out income by RMB622.5 million mainly in relation to licensing-out deals of QX030N and QX031N; (ii) increase of research and development service revenue by RMB16.7 million driven by growth of CDMO services by RMB35.5 million, partially offset by decrease of QX004N and QX008N service fee; and (iii) increase of SAILEXIN supply by RMB9.0 million, aligned with sales growth of SAILEXIN.

Cost of Sales

For the year ended December 31, 2025, our Group's cost of sales increased by RMB25.9 million from RMB66.6 million in 2024 to RMB92.5 million, which was mainly attributable to: (i) growth of overseas licensing-out deals; (ii) growth of CDMO services; and (iii) growth of SAILEXIN supply.

Research and Development Expenses

For the year ended December 31, 2025, our research and development expenses decreased by RMB81.1 million from RMB334.3 million in 2024 to RMB253.2 million in 2025, primarily attributable to (i) decrease of third party contracting costs by RMB46.4 million (which was mainly due to the completion of phase III clinical trial of QX002N); (ii) the costs for QX030N and QX031N were accounted in cost of sales and contract fulfillment costs by RMB21.3 million in total after entering into licensing agreements; and (iii) decrease of equity settled share-based payment expenses by RMB4.1 million.

Distribution and Selling Expenses

Distribution and selling expenses of RMB30.6 million mainly represent commission fee for licensing-out deals.

Cash and Cash Equivalents, Time Deposits and Financial Assets Measured at Fair Value through Profit or Loss (FVPL)

Our cash and cash equivalents, time deposits and financial assets measured at fair value through profit or loss (FVPL) increased by 87.4% from RMB556.1 million as of December 31, 2024 to RMB1,042.0 million as of December 31, 2025, mainly as a result of receiving upfront fee and milestone payment of QX030N, QX031N and QX005N of RMB653.1 million, net proceeds from placement of H Shares of RMB91.0 million and cash inflow from bank borrowings, partially offset by operating expenditure for current period.

Non-IFRSs Measures:⁽¹⁾

	2025	2024	Changes
	RMB'000	RMB'000	RMB'000
Profit/(Loss) for the year	307,444	(349,687)	657,131
<i>Add:</i>			
Equity-settled share-based payment expenses	48,753	75,460	(26,707)
Adjusted profit/(loss) for the year	<u>356,197</u>	<u>(274,227)</u>	<u>630,424</u>

⁽¹⁾ Adjusted profit/(loss) for the year represents the profit/(loss) for the year excluding the effect of certain non-cash items, namely the share-based compensation expenses. The term adjusted profit/(loss) for the year is not defined under IFRSs. The use of this non-IFRSs measure has limitations as an analytical tool, and you should not consider it in isolation from, or as a substitute for analysis of, our results of operations or financial condition as reported under IFRSs. Our presentation of this adjusted figure may not be comparable to similarly titled measures presented by other companies. However, we believe that this non-IFRSs measure reflects our core operating results by eliminating potential impacts of items that our management do not consider to be indicative of our core operating performance, and thus, facilitate comparisons of core operating performance from period to period and company to company to the extent applicable.

BUSINESS REVIEW**Overview**

Founded in 2015, we are a biotech company exclusively focused on biologic therapies for autoimmune and allergic diseases, fully covering dermatology, respiratory, gastroenterology and rheumatology. With an integrated strategy encompassing R&D, production and commercial collaboration, we have advanced five monoclonal antibody products to the marketing or Phase III clinical trial stage, and the domestic market will gradually embark on its revenue phase. Meanwhile, we entered into three overseas licensing transactions in 2025, marking a brilliant start to our globalization strategy and further strengthening our leading position in the autoimmune field through the efficient development of a series of bispecific antibody products.

As of the Latest Practicable Date, we have one commercialised product, namely SAILEXIN, China's first ustekinumab biosimilar, with domestic sales of close to RMB300 million (inclusive of VAT) in 2025. Two core products are progressing smoothly in development. In particular, Oturkibart (anti-IL-4R α mAb) has met the primary endpoints for the Phase III clinical trial in China for prurigo nodularis (PN) and atopic dermatitis (AD), and New Drug Applications (NDA) for these two indications are expected to be submitted successively within this year. The NDA for ankylosing spondylitis (AS) of Crusekitug (anti-IL-17A mAb) has been accepted. QX004N (anti-IL-23p19 mAb) and QX008N (anti-TSLP mAb) are in Phase III clinical trial for psoriasis (Ps) and for chronic obstructive pulmonary disease (COPD) in China, respectively, with partners accelerating their development. As our monoclonal antibody products gradually move towards the commercialization stage, the visibility of the Company's development continues to improve, and the Qyuns 1.0 layout is nearing completion.

Furthermore, leveraging our deep expertise in the autoimmune field, we have efficiently developed a series of long-acting bispecific antibody pipelines, maintaining our advantages in dermatology while deeply exploring the significant potential opportunities in areas such as respiratory diseases. Our successive collaborations with Caldera Therapeutics, Roche, and Windward Bio demonstrate our execution capabilities in implementing our global strategy. With QX030N (anti-IL-23p19/TL1A bsAb), QX031N (anti-TSLP/IL-33 bsAb), and QX027N (anti-TSLP/IL-13 bsAb) gradually entering the clinical stage, the Qyuns 2.0 iteration is setting sail at full throttle.

During the year ended December 31, 2025, we have successfully entered into three overseas strategic collaborations with the following business partners for the development and commercialization of our bispecific antibody products:

- ***QX030N/CLD-423***

In April 2025, we entered into an out-license agreement with Caldera Therapeutics and granted Caldera Therapeutics an exclusive right to develop and commercialize QX030N globally. As of the Latest Practicable Date, we have received cooperation payments of US\$15 million and a partial equity interest in Caldera Therapeutics. QX030N has initiated the overseas Phase I clinical trial.


- ***QX031N***

In October 2025, we entered into a global exclusive collaboration and license agreement with Roche and granted Roche the global exclusive right to develop, manufacture, and commercialize QX031N. As of the date of this announcement, we have received cooperation payments of US\$75 million, and subject enrollment has begun for the Phase I clinical trial of QX031N in New Zealand.

- ***QX027N/WIN027***

In December 2025, we entered into a license and collaboration agreement with LE2025 (an affiliate of Windward Bio) and granted LE2025 an exclusive right to develop and commercialize QX027N globally, except from mainland China, Taiwan, Hong Kong and Macau. As of the Latest Practicable Date, we have received upfront payments and respective equity shares in Windward Bio.

The following chart summarizes our portfolio of drug candidates as of the Latest Practicable Date:



Cautionary Statement required under Rule 18A.08(3) of the Listing Rules

There is no assurance that we will ultimately develop or market our Core Products successfully. Shareholders and potential investors of our Company are advised to exercise with caution when dealing in the Shares of our Company.

SAILEXIN (QX001S, Ustekinumab Injection)

SAILEXIN (QX001S, Ustekinumab Injection) was approved by the NMPA in October 2024 as China's first approved ustekinumab biosimilar and our Company's first commercialised product. Approved by the FDA in 2009, ustekinumab (Stelara®) was the first biologic treatment to selectively inhibit the IL-23 and IL-12 pathways and is one of the major treatments for Ps worldwide.

On March 3, 2025, Zhongmei Huadong, a subsidiary of Huadong Medicine and our commercialisation partner for SAILEXIN, received the Notice of Approval of Supplemental Application for Drugs from the NMPA, and the supplemental application for SAILEXIN to add the new indication of pediatric plaque Ps has been approved. In addition, SAILEXIN's supplemental application for Crohn's disease (CD) was submitted by Zhongmei Huadong in February 2025 and is expected to be approved in the first half of 2026. We expect SAILEXIN to be an affordable drug for a broad section of Ps and CD patients and the domestic sales of SAILEXIN (inclusive of VAT) in 2025 were close to RMB300 million.

Oturkibart (QX005N/HDM3016)

Being one of our Core Products, Oturkibart is an innovative humanized monoclonal antibody targeting IL-4R α . Through specific binding with IL-4R α , Oturkibart blocks the binding of IL-4R α with both IL-4 and IL-13, and also inhibits the signaling pathways and biological effects mediated by IL-4 and IL-13, thus exerting therapeutic effects on type 2 inflammatory allergic diseases. Oturkibart is one of only two anti-IL-4R α mAbs in China with breakthrough therapy designation (BTD).

As of the Latest Practicable Date, the primary endpoints of the Phase III clinical trial of Oturkibart for PN and AD have been met. We expect that the NDAs for PN and AD indications will be submitted in the first and second half of 2026, respectively.

In July 2024, we entered into a cooperation agreement (the "**QX005N Agreement**") with Zhongmei Huadong, pursuant to which Zhongmei Huadong will co-develop Oturkibart (Huadong Medicine R&D code: HDM3016) together with the Company within the Mainland China, Hong Kong, Macau and Taiwan (the "**Authorized Territory**"). The collaboration includes granting Zhongmei Huadong an exclusive right to jointly develop the subject product (with a 50/50 cost-sharing for Phase III clinical trials of specified indications), an exclusive optional right for market promotion, and a right of first refusal for the transfer of MAH.

Crusekitug (QX002N)

Being one of our Core Products, Crusekitug is a high-affinity monoclonal antibody targeting IL-17A, a key player in the pathological mechanism of various autoimmune diseases. IL-17A inhibitors are recommended by prevailing clinical guidelines as second-line standalone treatment (the same designation as TNF inhibitors) for AS patients with high disease activity after receiving first-line traditional treatments. Between the two classes of biologics (i.e., TNF inhibitors and IL-17A inhibitors), IL-17A inhibitors demonstrate significant clinical benefits for both TNF- α inhibitor-naïve patients and those who are intolerant to or unable to achieve adequate disease control with TNF- α inhibitors.

Phase III clinical trial data of Crusekitug was released through oral presentation at the 2025 annual meeting of the American College of Rheumatology (ACR Convergence). The results showed that the ASAS40 response rate at week 16 in the treatment group receiving 160 mg of Crusekitug administered every four weeks (Q4W) was 40.4%, which was significantly higher than the 18.9% observed in the placebo group ($P < 0.0001$). In addition, the ASAS20 response rate in the Crusekitug treatment group reached 65.2%, as compared to 41.3% in the placebo group ($P < 0.0001$). At week 52, the ASAS20 response rate in the Crusekitug treatment group reached 87.2%, and the ASAS40 response rate reached 70.2%. The trial successfully met both its primary endpoint and key secondary endpoints. The efficacy of the drug was also significant in the population previously treated with TNF inhibitors. Furthermore, Crusekitug effectively reduces edema and inflammation in the spine and sacroiliac joints of subjects, providing clear objective imaging evidence for the drug's ability to suppress disease activity.

The NDA for Crusekitug in the treatment of active ankylosing spondylitis in adults was accepted by the NMPA on March 9, 2026.

QX004N/HS-20137

QX004N (Hansoh Pharma R&D code: HS-20137) is an IL-23p19 inhibitor for the treatment of Ps and CD. IL-23p19 has emerged as a key target associated with superior efficacy for Ps patients with more severe symptoms or inadequate response to existing treatments.

In March 2025, Phase II clinical data for QX004N was disclosed by our partner Hansoh Pharma in a late-breaking oral presentation at the American Academy of Dermatology (AAD) Annual Meeting. As of the Latest Practicable Date, phase III clinical trial for Ps of QX004N is in progress.

In April 2024, we entered into an exclusive out licensing agreement (the “**QX004N Agreement**”) with Hansoh (Shanghai) for the research and development, manufacturing, and commercialisation of QX004N within the Authorized Territory. As of the Latest Practicable Date, the Company has received a total of RMB143.0 million in payments from Hansoh Pharma according to the QX004N Agreement.

QX008N/JKN2401

QX008N (Joincare R&D code: JKN2401) is a humanized IgG1 mAb targeting TSLP, designed for the treatment of moderate-to-severe asthma and moderate-to-severe COPD. TSLP-targeting therapy (represented by Tezspire® (tezepelumab)) is currently the only approved biologic drug for all phenotypes of asthma in the world. Whether based on baseline eosinophil counts or allergic status (without the need for pre-testing specific biomarkers such as blood eosinophil counts or IgE levels), it significantly reduces the risk of acute exacerbations and delays disease progression in these patients.

In January 2024, we entered into a technology transfer agreement (the “**QX008N Agreement**”) with Joincare to grant Joincare an exclusive license to develop, manufacture and commercialise QX008N in Mainland China, Hong Kong and Macau. As of the Latest Practicable Date, Joincare has initiated the Phase III clinical trial of QX008N for COPD in China and QX008N is the the fifth product in the Company's pipeline to be successfully advanced to Phase III stage.

Bispecific Antibody Products

We have developed a series of long-acting bispecific antibodies for autoimmune diseases, aiming to enhance clinical efficacy across multiple indications and extend dosing intervals to improve medication convenience:

QX027N/WIN027

QX027N is a long-acting anti-TSLPxIL-13 bispecific antibody, targeting AD and asthma indications. QX027N has obtained clinical trial approvals from the Center for Drug Evaluation of the National Medical Products Administration (Acceptance Nos.: CXSL2500757, CXSL2500758). On December 12, 2025, the Company successfully initiated the Phase I clinical trial for QX027N by enrolling the first subject in China. Phase II clinical trial is expected to be commenced in the second half of 2026.

In December 2025, we entered into a license and collaboration agreement with LE2025 (an affiliate of Windward Bio) and granted LE2025 an exclusive right to develop and commercialize QX027N globally, except from mainland China, Taiwan, Hong Kong and Macau. In return, the Group will be entitled to receive a total of up to US\$700 million payments, including an upfront payment, an equity interest of Windward Bio, development and commercial milestone payments, plus tiered royalties on net sales of QX027N in the above licensed territory.

QX030N/CLD-423

QX030N is a clinical stage long-acting bispecific antibody targeting the clinically validated IL-23p19 and TL1A pathways. Combining these two powerful autoimmune targets in a single molecule represents the next frontier in inflammatory bowel disease (IBD) treatment. QX030N is rationally designed to achieve a best-in-disease profile with optimized efficacy, safety, pharmacokinetics and developability. In January 2026, the first subjects were dosed in an overseas Phase I healthy volunteer trial of QX030N.

In April 2025, we entered into an out-license agreement with Caldera Therapeutics and granted Caldera Therapeutics an exclusive right to develop and commercialize QX030N globally, pursuant to which the Group received a non-refundable upfront payment of US\$10 million and certain equity interest in Caldera Therapeutics. Subject to the achievement of certain clinical development, regulatory and commercial milestones, the Group may also receive additional payments of up to US\$545 million, plus tiered royalties on net sales from Caldera Therapeutics during a specified time period after the first commercial sales of QX030N.

QX031N

QX031N is an investigational long-acting bispecific antibody that targets both human thymic stromal lymphopoietin (TSLP) and human interleukin-33 (IL-33). TSLP and IL-33 are proteins called alarmins that are released in the body in response to external factors such as allergens, viruses, pollution, and mechanical stimuli. They have been shown to be involved in respiratory diseases like COPD and asthma, and play important roles in the inflammatory processes. QX031N is expected to be developed for the treatment of respiratory diseases such as COPD and asthma, and holds the potential to become a “First-in-class” and “Best-in-disease” therapy.

As of the date of this announcement, subject enrollment has begun for the Phase I clinical trial of QX031N in New Zealand.

In October 2025, we entered into a global exclusive collaboration and license agreement with Roche and granted Roche the global exclusive right to develop, manufacture, and commercialize QX031N. We received a one-time, non-refundable, and non-creditable upfront payment of US\$75 million and is eligible to receive up to US\$995 million milestone payments associated with the development, regulatory approval, and commercialization of the product, as well as tiered royalties on potential future product sales.

QX035N

QX035N, an investigational long-acting bispecific antibody, targeting c-kit (a type III receptor tyrosine kinase) and another undisclosed target. C-kit is a master regulator of mast cells, which are the primary effector cells in some allergic diseases. QX035N is specifically designed to inhibit the differentiation, maturation, survival, proliferation and degranulation of mast cells, resulting in the reduction and depletion of mast cells for treatment of mast cell-driven diseases. We plan to submit IND application of QX035N in the second half of 2026 and vigorously promote the R&D of the next-generation c-kit products.

Furthermore, leveraging our extensive library of monoclonal antibody molecules for autoimmune targets and scientifically grounded synergy assessments, we are continuously evaluating the therapeutic and BD cooperation potential of a series of bispecific antibody molecules, and will prioritize and advance the most promising ones to IND filing and clinical stages.

Research and Development

Research and development (“**R&D**”) is the cornerstone of our sustained success. Currently, the Company has achieved significant R&D milestones: one monoclonal antibody drug has been approved for marketing, four innovative monoclonal antibody products have entered NDA or Phase III clinical trial stage, and three innovative bispecific antibody products have been licensed overseas, fully validating our R&D capabilities and the commercial value of our products. Continuously enhancing R&D capabilities and consistently delivering innovative products with potential differentiation advantages are critical to maintaining our industry competitiveness. The Company has established an industry-leading integrated antibody drug R&D platform, which includes the following key components: i) high-throughput monoclonal antibody discovery, screening and developability evaluation system: with an annual capacity to support early discovery for over 10 antibody projects, it efficiently identifies candidate molecules with potential differentiation advantages; ii) innovative bispecific antibody design and development platform: built on the existing monoclonal antibody pipeline, it enables rapid and efficient development of bispecific antibodies, significantly shortening R&D timelines; iii) comprehensive CMC development system: equipped with full-process capabilities, including antibody physicochemical characterization, production cell line construction, process development and formulation optimization; iv) translational medicine research platform: covering clinical pharmacology and translational research from preclinical to clinical stages.

With the core mission of improving patient clinical benefits and medication adherence, we highlight the differentiated advantages of our products, and actively explore combination therapies involving bispecific antibodies in our development strategy. Our R&D efforts are primarily focused on the following areas:

- ***Respiratory Diseases***

Addressing the transformative need for disease-modifying therapy (DMT) in asthma and chronic obstructive pulmonary disease (COPD), we aim to develop superior long-term treatment options that can delay, halt or even reverse disease progression while maintaining sustained efficacy to achieve the goal of clinical remission;

- ***Inflammatory Bowel Disease***

To overcome the limitations of current therapies in achieving clinical remission, we are developing innovative products that significantly improve both clinical and endoscopic remission rates and meet the alternative treatment needs of patients who have been treated with biologics;

- ***Skin Diseases***

Focusing on unmet clinical needs, including:

Atopic Dermatitis (AD): Exploring novel treatment strategies to achieve rapid symptom and lesion relief, reduce relapse risk, and significantly prolong time to recurrence;

Chronic Spontaneous Urticaria (CSU): Developing next-generation drugs capable of immediate symptom control, even in treatment-refractory patients.

The overall goal of bispecific antibody product development is to enhance drug efficacy, optimize dosing intervals, improve adherence, and reduce medication costs.

For the year ended December 31, 2025, our total R&D costs amounted to approximately RMB253.2 million.

The following table sets forth a breakdown of our R&D costs:

	Year ended December 31,	
	2025	2024
	<i>RMB'000</i>	<i>RMB'000</i>
Staff costs	53,567	66,987
Depreciation and amortization	7,587	16,125
Third party contracting costs	173,097	219,476
Raw materials and consumables	7,844	12,616
Others	11,077	19,073
	<hr/>	<hr/>
Total	253,172	334,277
	<hr/> <hr/>	<hr/> <hr/>

Manufacturing and Commercialization

Our production facility is meticulously constructed in strict compliance with the current Good Manufacturing Practice (cGMP) standards of China, the United States, and the European Union. At present, we have successfully obtained the Drug Manufacturing License. Moreover, in November 2024, the facility of Cellularforce passed the GMP compliance inspection for SAILEXIN drug substance and drug product manufacture organized by the NMPA. In September 2025, Cellularforce successfully passed an EU Qualified Person (QP) audit, confirming that its quality management system and production capacity met EU GMP standards. Our manufacturing site is located at our headquarters in Taizhou, Jiangsu, covering an area of 57,977 sq.m., including one drug substance production line and two formulation production lines. The drug substance production line has four 2,000 L single-use bioreactors and relevant downstream purification production line with an annual manufacturing capacity of approximately 300 kg therapeutic antibodies. The formulation production lines have one vial production line for 2 ml, 10 ml and 30 ml specifications, with a manufacturing capacity of 18,000 vials/hour, and one prefilled syringe fill-finish and packaging production line for 1 ml and 2 ml specifications, with a manufacturing capacity of 9,000 syringes/hour. We believe that our self-owned cGMP-standard manufacturing capability, coupled with our strong R&D capability, will allow us to achieve reliable cost control and ensure stable clinical and commercial drug supply to any supply chain disruptions.

Going forward, we will continue to leverage the strong networking of physician resources from our strategic partners to connect with participants in the drug sales and distribution chain, to prepare us for future commercial launches of our drug candidates. In the future, we plan to build a relatively small, indication-specialized in-house commercialization team, beginning with indications with relatively limited patient populations treated in a small number of key hospitals, leveraging our deep understanding of these indications and physician resources.

Intellectual Property

As of December 31, 2025, we held 53 patents in China, including 41 invention patents and 12 utility models, as well as 22 patents overseas. As of the same date, we also had 48 patent applications pending in China and overseas. In particular, with respect to our Core Products, we had 9 registered patents and 1 pending patent application for Crusekitug and 8 registered patents and 1 pending patent application for Oturkibart. All of our patents and patent applications are self-owned. As of December 31, 2025, we had registered 95 trademarks in the PRC and Hong Kong. As of the same date, we were also the registered owner of 21 domain names in the PRC. During the year ended December 31, 2025, we had not been involved in any material proceeding in respect of, and we had not received notice of any material claim of infringement of, any intellectual property rights that may be threatened or pending, in which we may be a claimant or a respondent that may have a material adverse impact on us.

Employees and Remuneration

As of December 31, 2025, the Group had 337 employees, all of whom were based in China.

The number of employees of the Group varies from time to time depending on need. The remuneration package of the Group's employees includes salary, bonus and equity incentives, which are generally determined by their qualifications, industry experience, position and performance. Our Company makes contributions to social insurance and housing provident funds in accordance with relevant laws and regulations.

Our Company has conditionally adopted an Employee Share Incentive Scheme to eligible participants for their contribution or potential contribution to the Group.

The total staff costs (including Directors' emoluments) incurred by the Group for the year ended December 31, 2025 was approximately RMB152.7 million, as compared to approximately RMB168.8 million for the year ended December 31, 2024.

For the year ended December 31, 2025, the Group did not experience any material labor disputes or strikes that may have a material adverse effect on the Group's business, financial condition or results of operations, or any difficulty in recruiting employees.

Future Outlook

Going forward, we plan to pursue the following strategies, which we believe will further strengthen our core competitive strengths and enable us to capture rising business opportunities:

- Continuously solidify our foundation to strive for the goal that at least five products will be approved for marketing by 2030 and significant sales volume achieved;
- Advance the R&D of bispecific antibody drug candidates and strategically expand our pipeline to meet the substantial therapeutic needs in the respiratory, IBD and dermatology fields;
- Continue to optimize CMC quality management system and improve production efficiency and enhance manufacturing capacity utilization;
- Cooperate with established pharmaceutical companies in commercialisation;
- Firmly implement the globalization strategy and further establish an efficient overseas clinical operations team; and
- Continue to recruit and develop talent.

Our Directors confirm that there has been no material adverse change in the financial or trading position or prospects of our Group since December 31, 2025 and up to the Latest Practicable Date.

FINANCIAL REVIEW

The following discussion is based on, and should be read in conjunction with, the financial information and the notes included elsewhere in this announcement.

	December 31, 2025 RMB'000	December 31, 2024 RMB'000
Revenue	806,961	158,793
Cost of sales	<u>(92,549)</u>	<u>(66,600)</u>
Gross profit	714,412	92,193
Other income	13,066	28,816
Other net (loss)/gain	(11,770)	3,747
Administrative expenses	(99,813)	(115,925)
Distribution and selling expenses	(30,588)	(926)
Research and development expenses	(253,172)	(334,277)
Impairment loss on trade receivables	<u>(2,607)</u>	<u>–</u>
Profit/(Loss) from operations	329,528	(326,372)
Finance costs	<u>(22,157)</u>	<u>(23,388)</u>
Profit/(Loss) before taxation	307,371	(349,760)
Income tax	<u>73</u>	<u>73</u>
Profit/(Loss) for the year	307,444	(349,687)
Earnings/(Loss) per share – Basic and diluted (<i>in RMB</i>)	<u>1.41</u>	<u>(1.53)</u>
Adjusted profit/(loss) for the year (as illustrated under “ Non-IFRS Measures ”)	<u>356,197</u>	<u>(274,227)</u>

The following discussion is based on, and should be read in conjunction with, the financial information and the notes included elsewhere in this announcement.

Analysis of our Key Items of our Results of Operations

Revenue

For the year ended December 31, 2025, the Group's revenue increased by RMB648.2 million from RMB158.8 million in 2024 to RMB807.0 million, which mainly derived from (i) increase of licensing-out income by RMB622.5 million mainly in relation to licensing-out deals of QX030N and QX031N; (ii) increase of research and development service revenue by RMB16.7 million driven by growth of CDMO services by RMB35.5 million, partially offset by decrease of QX004N and QX008N service fee; and (iii) increase of SAILEXIN supply by RMB9.0 million, aligned with sales growth of SAILEXIN.

Cost of Sales

For the year ended December 31, 2025, our Group's cost of sales increased by RMB25.9 million from RMB66.6 million in 2024 to RMB92.5 million, which was mainly attributable to: (i) growth of overseas licensing-out deals; (ii) growth of CDMO services; and (iii) growth of SAILEXIN supply.

Administrative Expenses

For the year ended December 31, 2025, our administrative expenses decreased by RMB16.1 million from RMB115.9 million in 2024 to RMB99.8 million, which was mainly attributable to decrease of equity settled share-based payment expenses.

Research and Development Expenses

For the year ended December 31, 2025, our research and development expenses decreased by RMB81.1 million from RMB334.3 million in 2024 to RMB253.2 million in 2025, primarily attributable to (i) decrease of third party contracting costs by RMB46.4 million (which was mainly due to the completion of phase III clinical trial of QX002N); (ii) the costs for QX030N and QX031N were accounted in cost of sales and contract fulfillment costs by RMB21.3 million in total after entering into licensing agreements; and (iii) decrease of equity settled share-based payment expenses by RMB4.1 million.

Distribution and Selling Expenses

Distribution and selling expenses of RMB30.6 million mainly represent commission fee for licensing-out deals.

Non-IFRSs Measures:⁽¹⁾

	2025	2024	Changes
	RMB'000	<i>RMB'000</i>	<i>RMB'000</i>
Profit/(Loss) for the year	307,444	(349,687)	657,131
<i>Add:</i>			
Equity-settled share-based payment expenses	48,753	75,460	(26,707)
Adjusted profit/(loss) for the year	356,197	(274,227)	630,424

⁽¹⁾ Adjusted profit/(loss) for the year represents the profit/(loss) for the year excluding the effect of certain non-cash items, namely the share-based compensation expenses. The term adjusted profit/(loss) for the year is not defined under IFRSs. The use of this non-IFRSs measure has limitations as an analytical tool, and you should not consider it in isolation from, or as a substitute for analysis of, our results of operations or financial condition as reported under IFRSs. Our presentation of this adjusted figure may not be comparable to similarly titled measures presented by other companies. However, we believe that this non-IFRSs measure reflects our core operating results by eliminating potential impacts of items that our management do not consider to be indicative of our core operating performance, and thus, facilitate comparisons of core operating performance from period to period and company to company to the extent applicable.

Analysis of our Key Items of our Financial Position

	December 31,	December 31,
	2025	2024
	RMB'000	<i>RMB'000</i>
Total current assets	1,116,668	616,725
Cash and cash equivalents, time deposits and financial assets measured at fair value through profit or loss (FVPL)	1,041,968	556,127
Inventories and other contract costs	38,058	8,774
Total non-current assets	483,658	367,152
Equity investment designated at FVOCI	134,864	–
Total assets	1,600,326	983,877
Total current liabilities	503,743	430,161
Trade and other payables	279,051	208,794
Contract liabilities	44,527	9,364
Total non-current liabilities	417,487	332,666
Total liabilities	921,230	762,827
Net current assets	612,925	186,564
Total equity	679,096	221,050

Cash and Cash Equivalents, Time Deposits and Financial Assets Measured at Fair Value through Profit or Loss (FVPL)

Our cash and cash equivalents, time deposits and financial assets measured at fair value through profit or loss (FVPL) increased by 87.4% from RMB556.1 million as of December 31, 2024 to RMB1,042.0 million as of December 31, 2025, which was mainly as a result of receiving upfront fee and milestone payment of QX030N, QX031N and QX005N of RMB653.1 million, net proceeds from placement of H Shares of RMB91.0 million and cash inflow from bank borrowings, partially offset by operating expenditure for current period.

Inventories and Other Contract Costs

We recorded inventories and other contract costs of RMB38.1 million as of December 31, 2025, mainly representing our contract costs of on-going CDMO projects.

Equity Investment Designated at FVOCI

Equity investment designated at FVOCI represents the Company's equity interest in Caldera Therapeutics in relation to overseas licensing of QX030N. The investment was initially valued as RMB96.8 million, and increased by RMB38.1 million with advancement of the pipeline.

Trade and Other Payables

Our trade and other payables increased from RMB208.8 million as of December 31, 2024 to RMB279.1 million as of December 31, 2025, primarily attributable to net effect of increase of RMB74.0 million of other payables and decrease of RMB14.2 million of trade payables. The increase of other payables was mainly due to a milestone payment of RMB35.0 million from Zhongmei Huadong under the QX005N Agreement and accrual of commission fee for licensing-out deals of RMB24.0 million.

Contract Liabilities

Contract liabilities of RMB44.5 million mainly represent part of advanced receipt of QX030N and QX031N to be recognized as revenue upon satisfaction of delivery of respective performance obligation.

Net Current Assets

The increase in our net current assets from RMB186.6 million as of December 31, 2024 to RMB612.9 million as of December 31, 2025 was as a result of receiving upfront fee and milestone payment from the licensing-out deals of QX030N and QX031N and net proceeds from placement of H Shares, partially offset by operating expenditure for current period.

Liquidity and Capital Resources

We mainly relied on capital contributions by our shareholders, equity financing, and upfront and milestone payment from our licensing-out deals as the major sources of liquidity as well as bank and other borrowings. As part of our treasury policy, our management monitors and maintains a level of cash and bank balances deemed adequate to finance our operations and mitigate the effects of fluctuations in cash flows. As our business develops and expands, we expect to generate more cash from profit sharing and product supply of SAILEXIN as well as debt financing, upfront and milestone fees from licensing-out deals, cost sharing from joint development of Oturkibart with Zhongmei Huadong, and CDMO services.

We have optimized our bank loan structure. As of December 31, 2025, the balance of 2-3 years term working capital loan accounting for 92.03% of the total working capital loan balance (December 31, 2024: 39.1%).

As of December 31, 2025, the unutilized credit facility for working capital use available to us amounted to RMB561.5 million.

Analysis of our Key Items of Cash flow Statement

	2025 RMB'000	2024 RMB'000
Net cash generated from/(used in) operating activities	<u>399,848</u>	<u>(186,087)</u>
Net cash generated from/(used in) investing activities	<u>118,689</u>	<u>(25,225)</u>
Net cash generated from financing activities	<u>93,727</u>	<u>351,811</u>
Net increase in cash and cash equivalents	612,264	140,499

For the year ended December 31, 2025, our net cash generated from operating activities amounted to RMB399.8 million, while net cash used in operating activities amounted to RMB186.1 million for 2024. The increase was primarily a result of receiving upfront fee and milestone payment of QX030N, QX031N and QX005N of RMB653.1 million, partially offset by operating expenditure in 2025.

For the year ended December 31, 2025, our net cash generated from investing activities amounted to RMB118.7 million, while net cash used in investing activities amounted to RMB25.2 million for the year ended December 31, 2024. The increase was primarily attributable to the net cash inflow from the redemption of wealth management product from banks for 2025.

For the year ended December 31, 2025, our net cash generated from financing activities decreased by RMB258.1 million to RMB93.7 million from RMB351.8 million for the year ended December 31, 2024. The decrease was a result of decrease of bank borrowings withdrawal and decreased equity financing.

Indebtedness

We had interest-bearing bank borrowings of approximately RMB525.7 million and RMB577.4 million as of December 31, 2024 and 2025, respectively, which primarily consist of a secured bank loan used to support the construction of our manufacturing facility and working capital bank loans to support our operation. The total amount of loans with a fixed interest rate was RMB126.0 million as of December 31, 2025 (2024: RMB200.0 million). The fixed interest rate ranged from 2.3% to 3.0% per annum as of December 31, 2025 (2024: 3.0-3.8% per annum).

Key Financial Ratios

The following table sets forth the key financial ratios for the dates indicated:

	As of December 31, 2025	As of December 31, 2024
Current Ratio ¹	2.2	1.4
Gearing Ratio ²	57.6%	77.5%

¹ Current ratio is calculated using current assets divided by current liabilities as of the same date.

² Gearing ratio is calculated based on total liabilities divided by total assets and multiplied by 100%.

Current Ratio

Our current ratio increased from 1.4 as of December 31, 2024 to 2.2 as of December 31, 2025, mainly attributable to the increase of cash inflow in relation to licensing-out deals and proceeds from placement of H Shares.

Gearing Ratio

Our gearing ratio decreased from 77.5% as of December 31, 2024 to 57.6% as of December 31, 2025, mainly attributable to significant increase of cash and cash equivalents, time deposits, as a result of receiving upfront fee and milestone payment from the licensing-out deals of QX030N and QX031N, and net proceeds from placement of H Shares.

Charges on Assets

The Group's land use right and manufacturing facilities in Taizhou have been pledged as collateral in July 2024 for a long term loan.

MARKET RISKS

The Group is exposed to various types of market risks and other financial risks, including cash flow and fair value interest rate risk, credit risk, liquidity risk and currency risk.

Credit risk

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in a financial loss to our Group. Our credit risk is primarily attributable to trade and other receivables. Our exposure to credit risk arising from cash and cash equivalents, time deposits and wealth management products is limited because the counterparties are reputable banks or financial institution, for which we consider to have low credit risks.

The Group's exposure to credit risk arising from trade and other receivables is influenced mainly by the individual characteristics of each customer. As at December 31, 2025, approximately 53.1% of the total trade receivables were due from our five largest debtors. The Group will review and monitor the level of exposure to ensure that follow-up actions are taken to recover overdue debts. In addition, at the end of each reporting year, the Group performs impairment assessment under expected credit loss model so as to ensure that adequate impairment losses are made. The carrying amounts of trade receivables and other receivables represent the Group's maximum exposure to credit risk in relation to financial assets.

Liquidity risk

Individual operating entities within our Group are responsible for their own cash management, including the short-term investment of cash surpluses and the raising of loans to cover expected cash demands, subject to approval by our Shareholders when the borrowings exceed certain predetermined levels of authority. Our policy is to regularly monitor our liquidity requirements and our compliance with lending covenants, to ensure that we maintain sufficient reserves of cash and readily realizable securities and adequate committed lines of funding from major financial institutions to meet our liquidity requirements in the short and long term.

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Our interest rate risk arises primarily from cash at bank, interest-bearing borrowings, time deposits with banks and lease liabilities. The Group's interest-bearing financial instruments at variable rates as at 31 December 2025 are the cash at bank and interest-bearing borrowings, and the cash flow interest risk arising from the change of market interest rate on these balances is not considered significant. We regularly review our strategy on interest rate risk management in light of the prevailing market condition.

The Group had not used any interest rate swaps to hedge its exposure to interest rate risk during the year ended December 31, 2025.

Foreign currency risk

We are exposed to currency risk primarily through cash and cash equivalents and time deposits which give rises to cash balances that are denominated in a foreign currency, i.e., a currency other than the functional currency of the operations to which the transactions relate. The currencies primarily relevant to this risk are the Hong Kong dollars and U.S. dollars. The Group does not enter into any hedging transactions to manage the potential fluctuation in foreign currency, but the management closely monitor the fluctuation of foreign currency rates on regular basis to set up appropriate strategy to mitigate the risk.

CAPITAL STRUCTURE

The shares of our Company were listed on Main Board of the Stock Exchange on the Listing Date. Save as disclosed in this announcement, there has been no material change in the capital structure of our Company since that date.

SIGNIFICANT INVESTMENTS AND MATERIAL ACQUISITIONS AND DISPOSALS

On 23 April 2025, the Group entered into a license-out agreement (the “**QX030N Agreement**”) with Caldera Therapeutics, under which Caldera Therapeutics was granted an exclusive right to develop and commercialise the product QX030N globally. In connection with the QX030N Agreement, the Company and Caldera Therapeutics have also entered into a share purchase agreement (the “**SPA**”) on the same date of the QX030N Agreement, under which the Group agrees to acquire the equity interest in Caldera Therapeutics. Pursuant to the QX030N Agreement, the Group received a non-refundable upfront payment of US\$10 million and approximately 24.88% of equity interest in Caldera Therapeutics. As at the date of the SPA, Caldera Therapeutics had no revenue or profit and none of the applicable percentage ratios under the Listing Rules in respect of such transactions under the SPA exceeded 5%. Accordingly, such a transaction was not subject to the announcement or shareholder approval requirements under Chapter 14 of the Listing Rules. Please refer to the announcement of the Company dated April 24, 2025 for details.

The acquisition of approximately 24.88% equity interest in Caldera Therapeutics under the SPA was completed on May 14, 2025. As of December 31, 2025, the Group’s shareholding in Caldera Therapeutics was diluted from 24.88% to approximately 14.81% after series A financing. As of January 8, 2026, Caldera Therapeutics has a total of US\$112.5 million capital raised. As of December 31, 2025, according to the latest Equity Valuation Report issued by Asia-Pacific Appraisal, the fair market value of our equity interest in Caldera Therapeutics, as mentioned above, was assessed at US\$19,187,000 (equivalent to RMB134,864,000), representing over 5% of the Company’s total asset value. As the Group does not participate in or influence the financial and operating policy decisions of Caldera Therapeutics, the Group concluded that it has no significant influence over Caldera Therapeutics and measured this equity investment at fair value. The investment was designated at FVOCI (non-recycling) for strategic purposes, with no dividends received during the period and no realized gains or losses recognized; only unrealized fair value gains were recorded in other comprehensive income. Please refer to Note 10 to the Consolidated Financial Statements for details. The acquisition is strategically aligned with the Company’s objective to enhance its global cooperation network through its innovative technology platforms and expand its business in the biopharmaceutical sector.

Save as disclosed above, our Company had no other significant investments, material acquisitions and/or disposals of subsidiaries, associates and joint ventures during the year ended December 31, 2025.

FUTURE PLANS FOR MATERIAL INVESTMENTS AND CAPITAL ASSETS

Save as disclosed in the section headed “USE OF PROCEEDS FROM THE GLOBAL OFFERING” in this announcement, the Group did not have plan for material investments and capital assets as of the date of this announcement.

MATERIAL ACQUISITIONS AND DISPOSALS OF SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES

The Group did not have any material acquisition or disposal of subsidiaries, associates and joint ventures during the year ended December 31, 2025.

OTHER INFORMATION

PURCHASE, SALE OR REDEMPTION OF OUR COMPANY’S SHARES OR SALE OF TREASURY SHARES

During the Reporting Period, the Company repurchased a total of 1,512,000 H Shares (the “**Repurchased Shares**”) on the Hong Kong Stock Exchange for a total consideration of approximately HK\$29,907,609 (excluding transaction fees). Details of the Repurchased Shares are as follows:

Month of Repurchase	Repurchased Number of Shares	Highest Price (HKD)	Lowest Price (HKD)	Total Consideration (excluding transaction fees) (HKD)
November	901,800	22.80	18.42	18,240,697
December	<u>610,200</u>	<u>22.00</u>	<u>17.80</u>	<u>11,666,912</u>
Total	<u>1,512,000</u>	–	–	<u>29,907,609</u>

The Repurchased Shares during the Reporting Period are held by the Company as treasury shares (as defined in the Listing Rules) and will be disposed of or utilised based on the comprehensive consideration of market conditions and the Company’s capital management needs.

As of December 31, 2025, the balance of the issued Shares of the Company was 227,071,600 Shares (including 1,512,000 treasury shares). The Repurchased Shares as referred to in the circular of the Company dated April 29, 2025 was for the purpose of safeguarding the value of the Company and the interests of the Shareholders.

Save as disclosed above, neither the Company nor its subsidiaries have purchased, sold or redeemed any of the Company’s listed securities (including sale of treasury shares) during the Reporting Period.

CORPORATE GOVERNANCE PRACTICES

The Board is committed to achieving high corporate governance standards. The Board believes that high corporate governance standards are essential in providing a framework for our Company to safeguard the interests of the Shareholders, enhance corporate value, formulate its business strategies and policies, and improve its transparency and accountability.

Save as disclosed below, our Company has adopted the principles and Code Provisions of the CG Code contained in Appendix C1 to the Listing Rules as the basis for the corporate governance practices of the Company during the Reporting Period and up to the date of this announcement. During the Reporting Period, the Company has complied with all applicable Code Provisions of the CG Code save and except for the following deviation:

Under the Code Provision C.2.1 of Part 2 of the CG Code, the roles of chairman and chief executive shall be separate and shall not be performed by the same individual. The Chairman and General Manager (equivalent to chief executive officer) of our Company are held by Mr. Qiu who is the founder of our Company and has extensive experience in the industry. Having served in our Company as the general manager since the very early stage of our Company, Mr. Qiu is in charge of overall management, R&D and business strategy of our Company. Despite the fact that the roles of our chairman of the Board and our general manager are both performed by Mr. Qiu which constitutes a deviation from Code Provision C.2.1 of the CG Code, the Board considers that vesting the roles of both chairman of the Board and general manager all in Mr. Qiu has the benefit of ensuring consistent leadership and more effective and efficient overall strategic planning of our Company. The balance of power and authority is ensured by the operation of our Board, which comprises experienced and diverse individuals. The Board currently comprises two non-executive Directors and three independent non-executive Directors as compared to three executive Directors. The Board has designated Mr. Fung Che Wai, Anthony, an independent non-executive Director, to assume the position of the lead independent non-executive Director (“**Lead INED**”) with effect from August 15, 2025. Therefore, the Board possesses a strong independent element in its composition. The Board will continue to review and monitor the practices of our Company with an aim of maintaining a higher standard of corporate governance.

Our Company is committed to enhancing its corporate governance practices used to regulate conduct and promote growth of its business and to reviewing such practices from time to time to ensure that we comply with the CG Code and align with the latest developments of our Company.

MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS

Our Company has adopted the Model Code as set out in Appendix C3 to the Listing Rules as its own code of conduct for dealing in securities of our Company by the Directors and Supervisors.

Specific enquiry has been made of all the Directors and Supervisors, all the Directors and Supervisors have confirmed that they have complied with the Model Code during the Reporting Period. No incident of non-compliance by the Directors and Supervisors was noted by our Company during the Reporting Period.

The Model Code for Securities Transactions by Directors also applies to all employees who, because of their office or employment, are likely to possess inside information in relation to the Company or its securities. No incident of non-compliance of the Model Code by the employees was noted by the Company.

FINAL DIVIDEND

The Board does not recommend the payment of final dividend for the year ended December 31, 2025.

EVENTS AFTER THE REPORTING PERIOD

1. On December 19, 2025, the Company and LE2025, an affiliate of Windward Bio, have entered into a license and collaboration agreement (the “**QX027N Agreement**”). The QX027N Agreement grants LE2025 an exclusive right to develop and commercialize QX027N globally, except from mainland China, Taiwan, Hong Kong and Macau. In return, the Group will be entitled to receive a total of up to US\$700 million payments, including an upfront payment, an equity interest of Windward Bio, development and commercial milestone payments, plus tiered royalties on net sales of QX027N in the above licensed territory. Please refer to the announcement of the Company dated December 22, 2025 for details.

As of the Latest Practicable Date, we have received upfront payments and respective equity shares in Windward Bio.

2. On January 14, 2026, the first subjects have been dosed in a Phase I healthy volunteer trial of QX030N/CLD-423, a bispecific antibody targeting the clinically validated IL-23p19 and TL1A pathways. Please refer to the announcement of the Company dated January 14, 2026 for details.
3. On March 9, 2026, the new drug application of Crusekitug injection (anti-IL-17A monoclonal antibody, R&D code: QX002N) independently developed by the Company has been accepted by the NMPA. Please refer to the announcement of the Company dated March 9, 2026 for details.
4. On March 23, 2026, in order to effectively utilize its idle funds, the Company entered into a subscription agreement with Shanghai Pudong Development Bank Co., Ltd. (“**PDB**”) to subscribe for a wealth management product offered by PDB with a principal amount of RMB100 million and a maturity date of September 23, 2026. Please refer to the announcement of the Company dated March 23, 2026 for details.

Save as disclosed in this annual results announcement, we are not aware of any material subsequent events from the end of the Reporting Period to the date of this annual results announcement.

SCOPE OF WORK OF THE AUDITOR

The figures in respect of the Group's consolidated statement of financial position, consolidated statement of profit or loss, consolidated statement of profit or loss and other comprehensive income and the related notes thereto for the year ended December 31, 2025 as set out in this announcement have been compared by the Group's auditor, KPMG, Certified Public Accountants, to the amounts set out in the audited consolidated financial statements of the Group for the year as approved by the Board of Directors on March 27, 2026. The work performed by KPMG in this respect did not constitute an audit, review or other assurance engagement in accordance with Hong Kong Standards on Auditing, Hong Kong Standards on Review Engagements or Hong Kong Standards on Assurance Engagements issued by the Hong Kong Institute of Certified Public Accountants and consequently no assurance has been expressed by the auditor.

AUDIT COMMITTEE AND REVIEW OF FINANCIAL STATEMENTS

The Group has established the Audit Committee with written terms of reference in compliance with Rule 3.21 of the Listing Rules and the Corporate Governance Code as set out in Appendix C1 to the Listing Rules.

The financial information for the year ended December 31, 2025 set out in this announcement has been reviewed by the Audit Committee. The Audit Committee was satisfied that the Company's audited financial information contained in this annual results announcement was prepared in accordance with applicable accounting standards. The Audit Committee has considered and reviewed the accounting principles and practices adopted by the Group, and discussed matters in relation to, among others, risk management, internal control and financial reporting of the Group with management and the Company's external auditor. The Audit Committee is of the view that the annual financial results for year ended December 31, 2025 have complied with relevant accounting standards, rules and regulations, and have been officially and properly disclosed. There is no disagreement between the Board and the Audit Committee regarding the accounting treatment adopted by the Company.

USE OF PROCEEDS FROM SHARE PLACING

In order to support the Company's ongoing and stable business development needs, further strengthening the Company's core competitive capabilities and ensuring sustainable growth, on August 25, 2025, the Company successfully placed a total of 5,000,000 new H Shares with nominal value of RMB1.00 each to one placee, namely TruMed Health Innovation Fund LP, who and whose ultimate beneficial owner(s) are independent persons and not connected persons of the Company, at the placing price of HK\$20.0 per H Share (a discount of approximately 10.95% to the closing price of HK\$22.46 per H Share quoted on the Hong Kong Stock Exchange on August 15, 2025 (being the last trading day before the placing price is fixed) (the "Placing"). The net placing price, after deducting placing fees and other relevant costs and the expenses of the Placing, is therefore approximately HK\$19.8 per H Share.

The net proceeds from the Placing (the "Proceeds from the Placing") amounted to approximately HK\$99.0 million. The Company intends to use the net proceeds for the purposes set forth below:

	Net proceeds for related purposes (HK\$'000,000)	Percentage of total net proceeds (%)	Actual utilized amount proceeds as of December 31, 2025 (HK\$'000,000)	Unutilized amount of proceeds as of December 31, 2025 (HK\$'000,000)	Expected timeline for unutilized amount
Repayment of existing interest-bearing bank borrowings	59.4	60.0%	22.1	37.3	By the end of 2027
Research and development of new pipeline of the Company including QX027N, QX031N and QX035N	29.7	30.0%	–	29.7	By the end of 2028
General working capital and others	9.9	10.0%	–	9.9	By the end of 2027
Total	<u>99.0</u>	<u>100.0%</u>	<u>22.1</u>	<u>76.9</u>	

The Company has utilized the net Proceeds from the Placing in accordance with the proposed uses as set out in the aforementioned announcements and schemes. For details of the Placing, the intended use and the useful life of the Proceeds from the Placing, please refer to the announcements of the Company dated August 18 and August 25, 2025.

USE OF PROCEEDS FROM THE GLOBAL OFFERING

The H Shares of our Company were listed on the Main Board of the Stock Exchange on March 20, 2024. The net proceeds received from the Global Offering, after deducting the underwriting fees and commissions and expenses payable by our Company in connection with the Global Offering, amounted to approximately HK\$163.3 million. As of December 31, 2025, our Company had utilize HK\$51.6 million of the proceeds from the Global Offering. The Board, after considering factors as set out below in the paragraph headed “Reasons for and benefits of the Change in Use of Proceeds”, has resolved to change the use of the unutilized portion of the net proceeds as illustrated in the table below:

The breakdown of our expected uses of proceeds from the Global Offering and expected timeline for unutilized amount is as follows:

	Original				Revised			Expected timeline for unutilized amount
	Net proceeds for related purposes (HK\$'000,000)	Percentage of total net proceeds (%)	Actual utilized proceeds as of December 31, 2025 (HK\$'000,000)	Unutilized amount of proceeds as of December 31, 2025 (HK\$'000,000)	Net proceeds for related purposes subsequent to re-allocation (HK\$'000,000)	Percentage of total net proceeds subsequent to re-allocation (%)	Unutilized amount of proceeds as of December 31, 2025 subsequent to re-allocation	
(i) Development and registration of our Core Product, QX002N:	49.2	30.1%	18.3	30.9	46.6	28.5%	28.3	By the end of 2027
(a) Fund the Phase III clinical trials (including costs for trial sites, CROs and subject enrollment) of QX002N in China for the treatment of AS	46.6	28.5%	18.3	28.3	46.6	28.5%	28.3	By the end of 2027
(b) CMC costs and the preparation of requisite registration filings of QX002N	2.6	1.6%	-	2.6	-	0.0%	-	N/A
(ii) Development and registration of our other Core Product, QX005N:	89.1	54.6%	28.9	60.2	78.8	48.2%	49.9	By the end of 2028
(a) Fund the clinical trials (including costs for trial sites, CROs and subject enrollment) of QX005N in China for the treatment of AD in adults:	44.1	27.0%	15.8	28.3	44.1	27.0%	28.3	By the end of 2028
(1) Phase II clinical trial	0.9	0.5%	0.9	-	0.9	0.6%	-	By the end of 2026
(2) Phase III clinical trial	43.2	26.5%	14.9	28.3	43.2	26.4%	28.3	By the end of 2028
(b) Fund the clinical trials (including costs for trial sites, CROs and subject enrollment) of QX005N in China for the treatment of PN	35	21.5%	11.5	23.5	33.1	20.2%	21.6	By the end of 2028
(1) Phase II clinical trial	3.1	1.9%	1.2	1.9	1.2	0.7%	-	By the end of 2026
(2) Phase III clinical trial	31.9	19.6%	10.3	21.6	31.9	19.5%	21.6	By the end of 2028
(c) Fund the Phase II clinical trials (including costs for trial sites, CROs and subject enrollment) of QX005N in China for the treatment of CRSwNP	2.1	1.3%	1.6	0.5	1.6	1.0%	-	By the end of 2026
(d) CMC costs and the preparation of requisite registration filings of QX005N	7.9	4.8%	-	7.9	-	0.0%	-	N/A

	Original				Revised		Unutilized amount of proceeds as of December 31, 2025 subsequent to re-allocation	Expected timeline for unutilized amount
	Net proceeds for related purposes (HK\$'000,000)	Percentage of total net proceeds (%)	Actual utilized amount proceeds as of December 31, 2025 (HK\$'000,000)	Unutilized amount of proceeds as of December 31, 2025 (HK\$'000,000)	Net proceeds for related purposes subsequent to re-allocation (HK\$'000,000)	Percentage of total net proceeds subsequent to re-allocation (%)		
(iii) Development and registration of QX004N, including costs for trial sites, CROs and subject enrollment for the Phase Ib and Phase II clinical trials of QX004N for the treatment of Ps and the Phase Ib and Phase II clinical trials of QX004N for the treatment of CD, and CMC costs of QX004N	14.2	8.7%	3.2	11	3.7	2.3%	0.5	By the end of 2026
(iv) Clinical development of QX006N, including the clinical trials (including costs for trial sites, CROs and subject enrollment), preparation of registration filings and CMC costs of QX006N	3.1	1.9%	0.6	2.5	0.6	0.4%	–	By the end of 2026
(v) Research and development of certain of our other assets, including QX007N, QX010N and QX013N, and drug discovery	7.7	4.7%	0.6	7.1	0.6	0.4%	–	By the end of 2026
(vi) Clinical development of QX027N, including the clinical trials (including costs for trial sites, CROs and subject enrollment), preparation of registration filings and CMC costs of QX027N					33.0	20.2%	33.0	By the end of 2028
Total	163.3	100.0%	51.6	111.7	163.3	100.0%	111.7	

REASONS FOR AND BENEFITS OF THE PROPOSED CHANGE IN USE OF PROCEEDS

The proposed change in use of proceeds is primarily based on the Company's strategic review of its overall R&D pipeline and considerations for optimizing the allocation of its resources. Since the proceeds were received, the Company has prioritized using bank loans, to make advance investments in the projects originally intended to be funded by the proceeds. As of the Latest Practicable Date, the R&D tasks originally planned for investment have been substantially performed. It is expected that no further proceeds will be used for the aforementioned projects in the future.

Given that the R&D tasks already implemented for the original projects have achieved their phased objectives, and taking into account the Company's long-term strategic planning and current development needs, to further focus on the R&D progress of future core product pipelines and to enhance the overall utilization efficiency of the proceeds and the implementation capacity of the funded projects, the Company, after careful consideration, proposes to reallocate the remaining proceeds originally intended for the aforementioned projects to the development of the Company's future R&D project, QX027N. This change will facilitate the Company's efficient integration of internal and external resources, optimize its pipeline layout, and is in line with the Company's long-term development strategy.

In view of the above, the Board considers the aforesaid change in use of proceeds will enable the Company to deploy its financial resources more effectively and will satisfy the current needs of the Group as the business continues to develop. The Board confirms that there is no material change in the principal business nature of the Group as set out in the Prospectus and considers that the change in use of proceeds is in line with the overall business strategy of the Group and will not have any material adverse impact on its operations and is in the best interests of the Company and its shareholders as a whole.

The Board will continuously assess the plan for the use of the unutilized portion of the net proceeds from the Global Offering and may revise or amend such plan where necessary to respond to the changing market conditions and strive for better business performance of the Group.

The aforementioned Change in Use of Proceeds is subject to the approval by the Shareholders at the AGM to be held by the Company.

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

The Board proposes to amend the Articles of Association in view of the amendments to The Company Law of the People's Republic of China (《中華人民共和國公司法》) has come into force on 1 July 2024. The main aspects of the proposed amendments of the Articles of Association are: (i) amend the registered capital of the Company; (ii) remove the establishment of the supervisory committee of the Company; and (iii) consequential amendments to the Articles of Association as a result of the legal and regulatory changes.

In order to reflect and align with the amendments to the Articles of Association, the Board proposes to make certain amendments to the Rules of Procedures for the General Meeting of Shareholders and the Rules of Procedures for the Board of Directors.

Prior to the amendments to the Articles of Association, the Rules of Procedures for the General Meeting of Shareholders and the Rules of Procedures for the Board of Directors being approved at the AGM, the existing Articles of Association, the Rules of Procedures for the General Meeting of Shareholders and the Rules of Procedures for the Board of Directors shall remain valid. The proposed amendments to the Articles of Association, the Rules of Procedures for the General Meeting of Shareholders and the Rules of Procedures for the Board of Directors are prepared in Chinese language. In the event of any discrepancy between the English translation and the Chinese version, the Chinese version shall prevail.

The Board has resolved to propose a resolution at the AGM to authorise the Board to delegate the management of the Company to handle the approval and filing procedures with relevant regulatory authorities involved in such amendments, and to make adjustments to the wordings of such amendments to the Articles of Association, the Rules of Procedures for the General Meeting of Shareholders and the Rules of Procedures for the Board of Directors according to opinions of the regulatory authorities.

PROPOSED ADOPTION OF THE 2026 SHARE INCENTIVE SCHEME

The Board has resolved to propose the adoption of the share incentive scheme (“**2026 Share Incentive Scheme**”).

The purposes of the 2026 Share Incentive Scheme are: (i) to establish and improve a long-term incentive mechanism for the Company; and (ii) to attract and retain certain eligible participants to promote the development and success of the business of the Group. The 2026 Share Incentive Scheme is intended to be implemented with new H Shares, treasury shares (if any) or existing H shares to be allotted and issued by the Company and will constitute a share scheme involving issue of new shares by the Company under Chapter 17 of the Listing Rules. The provisions of the 2026 Share Incentive Scheme will comply with Chapter 17 of the Listing Rules. The 2026 Share Incentive Scheme is subject to, among other things, (i) the passing of a special resolution at the AGM; and (ii) the listing committee of the Stock Exchange granting the approval for the listing of, and permission to deal in, new H Shares to be allotted and issued underlying the share awards granted under the 2026 Share Incentive Scheme.

The Board considers that the said proposed amendments to the Articles of Association, the Rules of Procedures for the General Meeting of Shareholders and the Rules of Procedures for the Board of Directors are in the interests of the Company and the Shareholders as a whole. The proposed amendments to the Articles of Association, the Rules of Procedures for the General Meeting of Shareholders and the Rules of Procedures for the Board of Directors are subject to the consideration and approval by the Shareholders by way of special resolution at the AGM. The AGM will also be convened to consider and, if thought fit, approve, among others, the adoption of the 2026 Share Incentive Scheme.

A circular containing, among others, (i) proposed amendments to the Articles of Association; (ii) proposed amendments to the Rules of Procedures for the General Meeting of Shareholders; (iii) proposed amendments to the Rules of Procedures for the Board of Directors; (iv) information on the 2026 Share Incentive Scheme; and (v) notices convening the AGM will be despatched to Shareholders in due course.

PUBLICATION OF ANNUAL RESULTS ANNOUNCEMENT AND ANNUAL REPORT

This results announcement is published on the websites of the Stock Exchange (<http://www.hkexnews.hk>) and the Company (www.qyuns.net). The annual report of the Group for the year ended December 31, 2025 containing all the relevant information required by the Listing Rules will be published on the websites of the Stock Exchange and the Company, in accordance with the Listing Rules in due course.

CLOSURE OF THE REGISTER OF MEMBERS

To determine the eligibility of the Shareholders to attend and vote at the AGM to be held on Friday, May 29, 2026, the register of members will be closed from Tuesday, May 26, 2026 to Friday, May 29, 2026, both days inclusive, during which period no transfer of shares will be effected. In order to be entitled to attend and vote at the AGM, all transfer forms accompanied by the relevant share certificates must be lodged with the Hong Kong H Share Registrar, Tricor Investor Services Limited, 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, for registration not later than 4:30 p.m. on Friday, May 22, 2026.

CONSOLIDATED STATEMENT OF PROFIT OR LOSS

For the year ended 31 December 2025

(Expressed in Renminbi Yuan)

	Note	2025 RMB'000	2024 RMB'000
Revenue	5	806,961	158,793
Cost of sales		<u>(92,549)</u>	<u>(66,600)</u>
Gross profit		714,412	92,193
Other income	6	13,066	28,816
Other net (loss)/gain		(11,770)	3,747
Distribution and selling expenses		(30,588)	(926)
Administrative expenses		(99,813)	(115,925)
Research and development expenses		(253,172)	(334,277)
Impairment loss on trade receivables		(2,607)	–
Profit/(loss) from operations		329,528	(326,372)
Finance costs	7(a)	<u>(22,157)</u>	<u>(23,388)</u>
Profit/(loss) before taxation	7	307,371	(349,760)
Income tax	8	<u>73</u>	<u>73</u>
Profit/(loss) for the year		<u>307,444</u>	<u>(349,687)</u>
Attributable to:			
Equity shareholders of the Company		314,450	(335,574)
Non-controlling interests		<u>(7,006)</u>	<u>(14,113)</u>
Profit/(loss) for the year		<u>307,444</u>	<u>(349,687)</u>
Earnings/(loss) per share			
Basic and diluted (RMB)	9	<u>1.41</u>	<u>(1.53)</u>

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME*For the year ended 31 December 2025**(Expressed in Renminbi Yuan)*

	2025	2024
	RMB'000	RMB'000
Profit/(loss) for the year	307,444	(349,687)
Other comprehensive income for the year (after tax and reclassification adjustments)		
Items that will not be reclassified to profit or loss:		
Equity investments at FVOCI – net movement in fair value reserves (non-recycling)	<u>38,070</u>	<u>–</u>
Other comprehensive income for the year	<u>38,070</u>	<u>–</u>
Total comprehensive income for the year	<u>345,514</u>	<u>(349,687)</u>
Attributable to:		
Equity shareholders of the Company	352,520	(335,574)
Non-controlling interests	<u>(7,006)</u>	<u>(14,113)</u>
Total comprehensive income for the year	<u>345,514</u>	<u>(349,687)</u>

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

(Expressed in Renminbi Yuan)

		31 December 2025	31 December 2024
	<i>Note</i>	RMB'000	<i>RMB'000</i>
Non-current assets			
Property, plant and equipment		287,936	312,315
Right-of-use assets		21,889	21,743
Intangible assets		2,457	3,473
Equity investment designated at fair value through other comprehensive income (“FVOCI”)	<i>10</i>	134,864	–
Other non-current assets		36,512	29,621
		<hr/> 483,658	<hr/> 367,152
Current assets			
Inventories and other contract costs	<i>11</i>	38,058	8,774
Trade and other receivables	<i>12</i>	36,642	51,824
Financial assets measured at fair value through profit or loss (“FVPL”)		–	195,439
Time deposits		80,220	–
Cash and cash equivalents		961,748	360,688
		<hr/> 1,116,668	<hr/> 616,725
Current liabilities			
Trade and other payables	<i>13</i>	279,051	208,794
Contract liabilities	<i>14</i>	44,527	9,364
Interest-bearing borrowings	<i>15</i>	177,951	210,582
Provisions		942	–
Lease liabilities		1,272	1,421
		<hr/> 503,743	<hr/> 430,161
Net current assets		<hr/> 612,925	<hr/> 186,564
Total assets less current liabilities		<hr/> 1,096,583	<hr/> 553,716

CONSOLIDATED STATEMENT OF FINANCIAL POSITION (CONTINUED)*(Expressed in Renminbi Yuan)*

		31 December 2025	31 December 2024
	<i>Note</i>	RMB'000	<i>RMB'000</i>
Non-current liabilities			
Interest-bearing borrowings	15	399,447	315,120
Deferred income		16,435	16,734
Lease liabilities		1,338	472
Deferred tax liabilities		267	340
		<u>417,487</u>	<u>332,666</u>
NET ASSETS		<u>679,096</u>	<u>221,050</u>
CAPITAL AND RESERVES			
Share capital		227,072	222,072
Reserves		466,957	6,905
Total equity attributable to equity shareholders of the Company		694,029	228,977
Non-controlling interests		<u>(14,933)</u>	<u>(7,927)</u>
TOTAL EQUITY		<u>679,096</u>	<u>221,050</u>

CONDENSED CONSOLIDATED CASH FLOW STATEMENT*(Expressed in Renminbi Yuan)*

	2025 RMB'000	2024 <i>RMB'000</i>
Net cash generated from/(used in) operating activities	<u>399,848</u>	<u>(186,087)</u>
Net cash generated from/(used in) investing activities	<u>118,689</u>	<u>(25,225)</u>
Net cash generated from financing activities	<u>93,727</u>	<u>351,811</u>
Net increase in cash and cash equivalents	612,264	140,499
Cash and cash equivalents at the beginning of the year	360,688	216,300
Effect of foreign exchange rate changes	<u>(11,204)</u>	<u>3,889</u>
Cash and cash equivalents at the end of the year	<u>961,748</u>	<u>360,688</u>

NOTES TO THE FINANCIAL STATEMENTS

(Expressed in Renminbi unless otherwise indicated)

1 GENERAL INFORMATION

Qyuns Therapeutics Co., Ltd. (the “**Company**”) (江蘇荃信生物醫藥股份有限公司), formerly known as Qyuns Therapeutics Co., Ltd. (江蘇荃信生物醫藥有限公司) was established in Taizhou, Jiangsu Province, People’s Republic of China (the “**PRC**”) on 16 June 2015 as a company with limited liability. Upon approval by the Company’s board meeting held on 2 September 2021, the Company was converted from a company with limited liability into a joint stock company with limited liability. The Company’s H shares were listed on the Main Board of the Stock Exchange of Hong Kong Limited on 20 March 2024.

The Company and its subsidiaries (together, “**the Group**”) are principally engaged in the research and development, manufacturing and commercialisation of biologic therapies for autoimmune and allergic diseases.

2 STATEMENT OF COMPLIANCE

These financial statements have been prepared in accordance with IFRS Accounting Standards, which collective term includes all applicable individual International Financial Reporting Standards (“**IFRSs**”), International Accounting Standards (“**IASs**”) and Interpretations issued by the International Accounting Standards Board (“**IASB**”) and the requirements of the Hong Kong Companies Ordinance. These financial statements also comply with the applicable disclosure provisions of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. Material accounting policies adopted by the Group are disclosed below.

The IASB has issued certain new or amended IFRS Accounting Standards that are first effective or available for early adoption for the current accounting period of the Group. Note 4 provides information on any changes in accounting policies resulting from initial application of these developments to the extent that they are relevant to the Group for the current accounting period reflected in these financial statements.

3 BASIS OF PREPARATION OF THE FINANCIAL STATEMENTS

The consolidated financial statements for the year ended 31 December 2025 comprise the Company and its subsidiaries (together referred to as the “**Group**”).

The measurement basis used in the preparation of the financial statements is the historical cost basis except that the assets are stated at their fair value as explained in the accounting policies.

The preparation of financial statements in conformity with IFRS Accounting Standards requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

4 CHANGES IN ACCOUNTING POLICIES

The Group has applied amendments to IAS 21, *The effects of changes in foreign exchange rates – Lack of exchangeability* issued by the IASB to these financial statements for the current accounting period. The amendments do not have a material impact on these financial statements as the Group has not entered into any foreign currency transactions in which the foreign currency is not exchangeable into another currency.

The Group has not applied any new standard or interpretation that is not yet effective for the current accounting period.

5 REVENUE AND SEGMENT REPORTING

(a) Revenue

The Group is principally engaged in the research and development, manufacturing and commercialisation of biologic therapies for autoimmune and allergic diseases. During the year ended 31 December 2025, the Group's revenue was mainly derived from license agreements by granting licenses of certain intellectual properties to customers, providing research and development services in relation to certain licensed products to the customers, etc.

(i) Disaggregation of revenue

Disaggregation of revenue from contracts with customers by major service lines and the timing of revenue recognition is as follows:

	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
Revenue from contracts with customers within the scope of IFRS 15		
Revenue from grant of licenses	723,442	100,943
Revenue from provision of research and development services	72,381	55,708
Sales of products	11,138	2,142
	<u>806,961</u>	<u>158,793</u>
Disaggregated by timing of revenue recognition		
– Point in time	801,061	126,846
– Over time	5,900	31,947
	<u>806,961</u>	<u>158,793</u>

Revenue from each major customer which accounted for 10% or more of the Group's revenue is set out below:

	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
Customer A	504,602	–
Customer B	197,798	–
Customer C	–*	100,880
Customer D	–*	32,061
Customer E	–*	17,285

* The revenue contribution was less than 10% of the Group's revenue.

- (ii) Revenue expected to be recognised in the future arising from contracts with customers in existence at the reporting date.

As at December 31, 2025, the aggregated amount of the transaction price allocated to the remaining performance obligations under the Group's existing contracts is RMB37,597,000 (2024: RMB8,218,000), which is expected to occur over the next 12 to 72 months.

The above amount does not include any amounts of milestone payments that the Group may earn in the future by meeting the conditions set out in the Group's existing contracts with customers, unless at the reporting date it is highly probable that the Group will satisfy the conditions for earning those bonuses.

The Group has also applied the practical expedient in paragraph 121 (a) of IFRS 15 to its sales contracts for pharmaceutical products and research and development service such that the above information does not include information about revenue that the Group will be entitled to when it satisfies the remaining performance obligations under the contracts for sales of pharmaceutical products and research and development service that had an original expected duration of one year or less.

(b) Segment and geographical information

For the purpose of making decisions about resources allocation and performance assessment, the Group's management focuses on the operating results of the Group as a whole. As such, the Group's resources are integrated, and no discrete operating segment information is available. Accordingly, no operating segment information is presented.

The following table sets out information about the geographical location of the Group's revenue from external customers.

	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
The People's Republic of China (the "PRC")	104,561	158,793
The United States	197,798	–
Switzerland	504,602	–
	<hr/>	<hr/>
Total	806,961	158,793
	<hr/> <hr/>	<hr/> <hr/>

6 OTHER INCOME

	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
Government grants (i)	2,374	16,712
Interest income from bank deposits	8,510	7,780
Net realised and unrealised gains on financial assets measured at FVPL	2,090	4,236
Others	92	88
	<hr/>	<hr/>
	13,066	28,816
	<hr/> <hr/>	<hr/> <hr/>

- (i) Government grants mainly represent (i) government subsidies for encouragement of research and development activities and compensation on the incurred interest expenses of bank loans, which were recognised in profit or loss when received; (ii) government subsidies for compensation on certain capital expenditure incurred for the construction of manufacturing facilities, which were amortised in profit or loss over the estimated useful lives of the relevant assets.

7 PROFIT/(LOSS) BEFORE TAXATION

Profit/(loss) before taxation is arrived at after charging:

(a) Finance costs

	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
Interest on lease liabilities	54	59
Interest on interest-bearing borrowings	19,169	23,329
Other finance costs	2,934	–
	<u>22,157</u>	<u>23,388</u>
Total finance costs on financial liabilities not measured at FVPL	<u>22,157</u>	<u>23,388</u>

(b) Staff costs

	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
Salaries, wages and other benefits	96,411	86,131
Contributions to defined contribution retirement schemes (i)	7,543	7,205
Equity-settled share-based payment expenses	48,753	75,460
	<u>152,707</u>	<u>168,796</u>

- (i) Pursuant to the relevant labor rules and regulations in the PRC, the Company and its subsidiaries in the PRC to participate in defined contribution retirement benefit schemes (the “Schemes”) organised by the local government authorities whereby the Company and its subsidiaries in the PRC are required to make contributions to the Schemes based on certain percentages of the eligible employee’s salaries. The local government authorities are responsible for the entire pension obligations payable to the retired employees.

The Group has no other material obligation for the payment of retirement benefits associated with the scheme beyond the annual contributions described above.

(c) Other items

	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
Amortisation cost of intangible assets	1,144	1,048
Depreciation charge of property, plant and equipment	29,364	29,416
Depreciation charge of right-of-use assets	1,587	2,207
	<u>32,095</u>	<u>32,671</u>
Total amortisation and depreciation	<u>32,095</u>	<u>32,671</u>
Auditors’ remuneration		
– audit services	1,712	1,523
– other services	785	604
Listing expenses	–	5,952
Research and development expenses (i)	253,172	334,277
Cost of inventories	9,224	3,752

- (i) During the year ended 31 December 2025, research and development expenses include staff costs and depreciation and amortisation expenses of RMB61,154,000 (2024: RMB83,112,000), which are also included in the respective total amounts disclosed separately above.

8 INCOME TAX IN THE CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

(a) Taxation in the consolidated statements of profit or loss represents:

	2025 RMB'000	2024 <i>RMB'000</i>
Current tax – PRC Tax	–	–
Deferred tax	<u>(73)</u>	<u>(73)</u>
	<u>(73)</u>	<u>(73)</u>

(b) Reconciliation between tax expense and accounting loss at applicable tax rates:

	2025 RMB'000	2024 <i>RMB'000</i>
Profit/(loss) before taxation	<u>307,371</u>	<u>(349,760)</u>
Notional tax on profit/(loss) before taxation, calculated at the rates applicable to profits in the PRC (i)	76,843	(87,440)
Effect of preferential tax rate (ii)	(32,595)	–
Effect of additional deduction on research and development expenses (iii)	(26,379)	(70,078)
Tax effect of other non-deductible expenses	387	1,783
Tax effect of non-taxable income	(1,500)	–
Tax effect of deductible temporary differences not recognised	10,553	18,991
Tax effect of deductible temporary differences and unused tax losses not recognised, net of utilisation of tax losses for which no deferred tax asset was recognised in previous periods	<u>(27,382)</u>	<u>136,671</u>
Actual tax expense	<u>(73)</u>	<u>(73)</u>

- (i) Pursuant to the Enterprise Income Tax (the “EIT”) Law of the PRC (the “EIT Law”), the Company and its PRC subsidiaries are liable to EIT at a rate of 25% unless otherwise specified.
- (ii) Pursuant to the PRC Corporate Income Tax Law and its relevant regulations, entities that qualified as a high and new technology enterprise (“HNTE”) are entitled to a preferential income tax rate of 15%. The Company obtained its certificate of HNTE on 19 December 2025 and is entitled to a preferential income tax rate of 15% from 2025 to 2027.
- (iii) Under the EIT Law of the PRC and its relevant regulation, an additional 100% of qualified research and development expenses incurred would be allowed to be deducted from the taxable income for the year ended 31 December 2025.

9 EARNINGS/(LOSS) PER SHARE

(a) Basic earnings per share

The calculation of basic earnings per share for the year ended 31 December 2025 is based on the profit attributable to ordinary equity shareholders of the Company of RMB314,450,000 (2024: loss of RMB335,574,000) and the weighted average of 223,695,000 ordinary shares (2024: 219,439,000), calculated as follows:

Weighted average number of ordinary shares (basic)

	2025 '000	2024 '000
Ordinary shares at 1 January in issue	222,072	210,025
Issuance of H shares through initial public offering	–	9,414
Placing of new H shares	1,753	–
Effect of shares repurchased	(130)	–
	<u>223,695</u>	<u>219,439</u>
Weighted average number of ordinary shares at the end of the year	<u>223,695</u>	<u>219,439</u>

(b) Diluted earnings per share

There were no dilutive potential ordinary shares outstanding during the year ended 31 December 2025 and 2024. Hence, the diluted earnings per share were the same as basic earnings per share.

10 EQUITY INVESTMENT DESIGNATED AT FVOCI

	2025 RMB'000	2024 RMB'000
Unlisted equity investment, at fair value	<u>134,864</u>	<u>–</u>

On 23 April 2025, the Group entered into a license agreement (the “**QX030N Agreement**”) with Caldera Therapeutics, Inc. (“**Caldera Therapeutics**”), under which Caldera Therapeutics was granted an exclusive right to develop and commercialise the product QX030N globally. Pursuant to the QX030N Agreement, the Group received a non-refundable upfront payment of US\$10,000,000 and a certain number of equity shares in Caldera Therapeutics.

As the Group does not participate in or influence the financial and operating policy decisions of Caldera Therapeutics, the Group concluded that it has no significant influence over Caldera Therapeutics and measured this equity investment at fair value. In addition, the Group designated its investment in Caldera Therapeutics at FVOCI (non-recycling), as the investment is held for strategic purposes. No dividends were received from this investment during the period.

11 INVENTORIES AND OTHER CONTRACT COSTS

	2025 RMB'000	2024 RMB'000
Inventories		
Raw material	3,954	1,398
Work in progress	4,499	1,938
	<u>8,453</u>	<u>3,336</u>
Other contract costs		
Costs to fulfil contracts	29,605	5,438
	<u>38,058</u>	<u>8,774</u>

12 TRADE AND OTHER RECEIVABLES

	2025	2024
	RMB'000	<i>RMB'000</i>
Trade receivables, net of loss allowance	19,695	26,281
Prepaid expenses	16,125	24,520
Deposits	644	424
Interest receivables	–	491
Other debtors	178	108
	<u>36,642</u>	<u>51,824</u>

All of the trade and other receivables are expected to be recovered or recognised as expense within one year.

Aging analysis

As of the end of the reporting period, the aging analysis of trade debtors based on the invoice date and net of loss allowance, is as follows:

	2025	2024
	RMB'000	<i>RMB'000</i>
Within 6 months	<u>19,695</u>	<u>26,281</u>

Trade receivables are generally due within 60 to 180 days from the date of billing.

13 TRADE AND OTHER PAYABLES

	2025	2024
	RMB'000	<i>RMB'000</i>
Trade payables (i)	96,720	110,885
Payroll payables	43,793	33,373
Payables for purchases of property, plant and equipment	3,789	6,758
Payables for obtaining a license agreement	23,978	–
Accrued listing expenses	478	3,290
Other payables and accruals (ii)	110,293	54,488
	<u>279,051</u>	<u>208,794</u>

(i) As of the end of the reporting period, the aging analysis of trade payables based on the invoice date is as follows:

	2025	2024
	RMB'000	<i>RMB'000</i>
Within 12 months	<u>96,720</u>	<u>110,885</u>

All of the above balances classified as current liabilities are expected to be settled within one year.

- (ii) Other payables and accruals mainly represent the payables due to Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (杭州中美華東製藥有限公司) (“**Zhongmei Huadong**”) of RMB95,942,000 in relation to a cooperation agreement.

In July 2024, the Company entered into a cooperation agreement (the “**QX005N Agreement**”) with Zhongmei Huadong, one of the shareholders of the Company, with respect to the joint development and commercialisation of the product QX005N. Pursuant to which, the Company has granted to Zhongmei Huadong, in the authorised territory and in the authorised fields, (i) an exclusive right to jointly develop QX005N; (ii) an exclusive optional right to promote QX005N (the “**Optional Right**”); and (iii) a right of first refusal for the transfer of marketing authorization holder (“**MAH**”) of QX005N. In the event that Zhongmei Huadong chooses not to exercise the Optional Right, the Company shall return the payment received in full to Zhongmei Huadong, and shall pay Zhongmei Huadong an interest of 5% per annum on the entire amount received.

For the year ended 31 December 2025, the Company received a net payment of RMB16,160,000 from Zhongmei Huadong, comprising a milestone payment of RMB35,000,000 (2024: RMB45,000,000), net of clinical development expenses of RMB18,840,000 paid on behalf of the Company by Zhongmei Huadong. During 2025, Zhongmei Huadong incurred aggregate clinical development expenses of RMB20,287,000 on behalf of the Company (2024: RMB11,419,000), of which RMB12,866,000 remained outstanding as at 31 December 2025. The amounts received from Zhongmei Huadong and the unsettled clinical development expenses were recognised as financial liabilities of the Company as at 31 December 2025.

14 CONTRACT LIABILITIES

	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
Receipts in advance from customers	<u>44,527</u>	<u>9,364</u>
	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
At the beginning of the year	9,364	870
Decrease in contract liabilities as a result of recognising revenue during the year that was included in the contract liabilities at the beginning of the year	(9,364)	(870)
Increase in contract liabilities as a result of receipts in advance	<u>44,527</u>	<u>9,364</u>
Receipts in advance from customers	<u>44,527</u>	<u>9,364</u>

The contract liabilities mainly relate to the Group’s obligation to transfer goods or services to a customer for which advance considerations were received (or an amount of consideration is due) from customers. The amount is recognised as contract liability until the goods are delivered to the customer. The Group will recognise the expected revenue in future when or as the performance obligation has been satisfied. The amount of contract liabilities expected to be recognised as income after more than one year is RMB14,486,000. All of the other contract liabilities are expected to be recognised as income within one year.

15 INTEREST-BEARING BORROWINGS

(a) The analysis of the carrying amount of interest-bearing borrowings is as follows:

	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
Unsecured short-term bank loans (i)	29,800	179,483
Current proportion of unsecured long-term bank loans (i)	120,721	3,291
Current proportion of secured long-term bank loans (ii)	<u>27,430</u>	<u>27,808</u>
Within 1 year or on demand	<u>177,951</u>	<u>210,582</u>
Unsecured long-term bank loans (i)	223,457	111,700
Secured long-term bank loans (ii)	<u>175,990</u>	<u>203,420</u>
Non-current	<u>399,447</u>	<u>315,120</u>
	<u><u>577,398</u></u>	<u><u>525,702</u></u>

(i) As at 31 December 2025, the unsecured short-term bank loans and unsecured long-term bank loans bear interest rate from 2.3% to 3.5% (2024: 3.0% to 3.8%).

(ii) In June 2024, Cellularforce, a subsidiary of the Company, entered into a loan arrangement with two commercial banks in the PRC for the construction of its manufacturing facilities. The loan was secured by Cellularforce's land use right and its manufacturing facilities in Taizhou and guaranteed by the Company, and bear interest rate of 3.5% as at 31 December 2025 (2024: 3.9%).

(b) The analysis of the repayment schedule of bank loans is as follows:

	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
Within 1 year or on demand	<u>177,951</u>	<u>210,582</u>
After 1 year but within 2 years	203,677	123,630
After 2 years but within 5 years	195,770	152,660
After 5 years	<u>–</u>	<u>38,830</u>
	<u><u>399,447</u></u>	<u><u>315,120</u></u>
	<u><u>577,398</u></u>	<u><u>525,702</u></u>

16 DIVIDENDS

No dividends were paid or declared by the Company or any of its subsidiaries.

DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

“ankylosing spondylitis” or “AS”	a chronic progressive inflammatory disease that is primarily characterized by inflammation of the spinal joints, leading to reduced flexibility of the joints and stiffness in the spine over time
“Annual General Meeting” or “AGM”	the annual general meeting of our Company proposed to be held on May 29, 2026
“antibody”	a protein produced in response to and counteracting a specific antigen. Antibodies combine chemically with substances which the body recognizes as alien, such as bacteria, viruses and foreign substances in the blood
“ASAS20”	Assessment of Spondyloarthritis International Society 20, a widely used measurement of symptom improvement in AS patients, defined as (i) an improvement of no less than 20% from baseline (and absolute improvement from baseline of at least 1 on a 0-to-10 scale) in at least three of the following four domains: patient global assessment of disease, total back pain, function (as assessed by the Bath Ankylosing Spondylitis Functional Index) and inflammation, and (ii) an absence of deterioration from baseline (meaning a worsening of no less than 20% and absolute worsening of at least 1 on a 0-to-10 scale) in the remaining domain
“ASAS40”	Assessment of Spondyloarthritis International Society 40, defined as an improvement of no less than 40% in at least three of the four domains (same as ASAS20) with an absolute improvement of at least 2 on a 0-to-10 scale, and no worsening in the remaining domain
“associate(s)”	has the meaning ascribed to it under the Listing Rules
“atopic dermatitis” or “AD”	an immune-mediated inflammatory skin disease that causes dry, itchy and inflamed skin
“Audit Committee”	the audit committee of our Board
“Authorized Fields”	the fields where Oturkibart, alone or in combination with other products, is suitable for use in the diagnosis, prevention and treatment of all human diseases, for all indications, in any dosage form, in any dosage and in any packaging
“Authorized Territory”	the Greater China, including Mainland China, Hong Kong, Macau and Taiwan

“autoimmune”	with respect to any disorder or disease, an abnormal immune response of the body against substances and tissues normally present in the body
“biologics”	drug products derived from a variety of natural sources-human, animal, or microorganism-that may be produced by biotechnology methods and other cutting-edge technologies (in contrast to small-molecule drugs, which are chemically synthesized). Biologics can be composed of sugars, proteins or nucleic acids or complex combinations of these substances, or may be living entities, such as cells and tissues
“biosimilar”	a follow-on version of innovator biopharmaceuticals which are separately developed after patents protecting the innovator biopharmaceuticals have expired and have similar quality, safety and efficacy as the innovator biopharmaceuticals
“bispecific antibody” or “BsAb”	an antibody that can simultaneously recognize and bind to two different targets
“Board” or “Board of Directors”	the board of Directors
“Caldera Therapeutics”	Caldera Therapeutics, Inc. is a company newly incorporated in the United States, for the primary purpose of drug development and commercialization, including development and commercialization of QX030N. Caldera Therapeutics was founded by leading biotech investors Lilly Asia Ventures, Atlas Venture, and venBio
“CDMO”	a contract development and manufacturing organization, which provides support to the pharmaceutical industry by providing development and manufacturing services outsourced on a contract basis
“Cellularforce”	Jiangsu Cellularforce Biopharma Co., Ltd. (江蘇賽孚士生物技術有限公司), a company established in the PRC with limited liability on August 2, 2018 and an indirect non-wholly owned subsidiary of our Company which is owned as to 66% by Saifu Juli and 34% by Taizhou Huacheng
“CG Code” or “Corporate Governance Code”	the Corporate Governance Code contained in Appendix C1 to the Listing Rules, as amended, supplemented or otherwise modified from time to time
“cGMP”	current good manufacturing practice, regulations and procedures that provide for proper design, monitoring, and control of manufacturing processes and facilities
“China” or “PRC”	The People’s Republic of China, but for the purpose of this announcement and for geographical reference only and except where the context requires otherwise, references in this announcement to “China” and the “PRC” do not apply to Hong Kong, Macau and Taiwan

“chronic obstructive pulmonary disease” or “COPD”	a chronic inflammatory lung disease that causes obstructed airflow from the lungs, symptoms including breathing difficulty, cough and mucus production
“chronic rhinosinusitis with nasal polyps” or “CRSwNP”	a subgroup of chronic rhinosinusitis characterized by the presence of fleshy swellings (nasal polyps) that develop in the lining of the nose and paranasal sinuses
“chronic spontaneous urticaria” or “CSU”	the occurrence of urticaria for six weeks or longer with identifiable specific triggers
“clinical trial”	a research study for validating or finding the therapeutic effects and side effects of test drugs in order to determine the therapeutic value and safety of such drugs
“Code Provision(s)”	the principles and code provisions set out in the CG Code
“Companies Ordinance”	the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) as amended, supplemented or otherwise modified from time to time
“Company”	Qyuns Therapeutics Co., Ltd. (江蘇荃信生物醫藥股份有限公司) (formerly known as Qyuns Therapeutics Co., Ltd. (江蘇荃信生物醫藥有限公司)), a company established in the PRC with limited liability on June 16, 2015 which was converted into a joint stock company with limited liability on September 30, 2021
“Company Law” or “PRC Company Law”	the Company Law of the PRC (中華人民共和國公司法), as amended, supplemented or otherwise modified from time to time
“connected person(s)”	has the meaning ascribed to it under the Listing Rules
“connected transaction(s)”	has the meaning ascribed to it under the Listing Rules
“Controlling Shareholder(s)”	has the meaning ascribed to it under the Listing Rules and, unless the context requires otherwise, refers to Mr. Qiu, Mr. Yu Guo’an, Hangzhou Quanyi, Shanghai Quanyou and Xinfu Tongxin; and a Controlling Shareholder shall mean each or any of them
“Core Product(s)”	has the meaning ascribed to it in Chapter 18A of the Listing Rules; for the purpose of this announcement, our Core Products refers to Crusekitug and Oturkibart
“CRO”	a contract research organization, which provides support to the pharmaceutical industry by providing research and development services outsourced on a contract basis

“Crohn’s disease” or “CD”	a chronic, incurable inflammatory bowel disease that affects the lining of the digestive tract and can sometimes cause life-threatening complications. CD symptoms can include abdominal pain, diarrhea, weight loss, anemia and fatigue
“cytokine”	proteins secreted by cells in both innate and adaptive immune responses, which can regulate diverse functions in the immune response
“Director(s)”	the director(s) of our Company
“EIT Law”	the PRC Enterprise Income Tax Law (中華人民共和國企業所得稅法), as enacted by the NPC on March 16, 2007 and effective on January 1, 2008, as amended, supplemented or otherwise modified from time to time
“Employee Share Incentive Scheme”	the restricted share scheme approved and adopted by our Company on September 15, 2022
“endpoint”	with respect to a clinical study or trial, the outcome that is measured
“Global Offering”	the global offering of 12,046,400 H Shares as described in the Prospectus
“Group”, “our Group”, “the Group” or “we”	our Company and all of our subsidiaries (or our Company and anyone or more of its subsidiaries, as the context may require)
“H Share(s)”	shares of our Company for which an application has been made for listing and permission to trade on the Stock Exchange
“H Share Registrar”	Tricor Investor Services Limited
“Hangzhou Quanyi”	Hangzhou Quanyi Investment Management Partnership (General Partnership)* (杭州荃毅投資管理合夥企業(普通合夥)), a general partnership established in the PRC on May 15, 2015 and one of our Controlling Shareholders, which is owned as to 50% by Mr. Qiu and 50% by Mr. Yu Guo’an, both as its general partners acting in concert
“Hansoh”	Hansoh Pharmaceutical Group Company Limited (翰森製藥集團有限公司), a pharmaceutical company whose shares are listed on the Stock Exchange (stock code: 3692)
“Hansoh (Shanghai)”	Hansoh (Shanghai) Healthtech Co., Ltd.* (翰森(上海)健康科技有限公司), a wholly-owned subsidiary of Hansoh
“Hong Kong” or “HK”	the Hong Kong Special Administrative Region of the PRC
“Hong Kong dollar(s)” or “HK\$”	Hong Kong dollar(s), the lawful currency of Hong Kong

“Huadong Medicine”	Huadong Medicine Co., Ltd.* (華東醫藥股份有限公司), a pharmaceutical company whose shares are listed on the Shenzhen Stock Exchange (stock code: 000963)
“IGA”	the Investigator’s Global Assessment, a five-point scale that provides a global clinical assessment of AD severity ranging from 0 to 4 (clear, mild, moderate and severe disease)
“IgG”	human immunoglobulin G, the most common antibody type found in blood circulation that plays an important role in antibody-based immunity against invading pathogens
“IL”	interleukin, a type of cytokine-signaling molecule in the immune system to provoke an immune response in the body of a human and other animals
“immunogenicity”	the ability of a particular substance, such as an antigen or epitope, to provoke an immune response in the body of a human and other animal
“immunoglobulin” or “Ig”	also known as antibody, a glycoprotein molecule produced by plasma cell (white blood cell)
“in vitro”	a medical study or experiment which is done in the laboratory within the confines of a test tube or laboratory dish
“Independent Third Party(ies)”	individuals or company(ies), who or which, to the best of our Directors’ knowledge, information and belief, having made all reasonable enquiries, is not a connected person of our Company within the meaning of the Listing Rules
“inhibitor”	a substance added or applied to another substance to slow down a reaction or to prevent an unwanted chemical change
“Joincare”	Joincare Pharmaceutical Group Industry Co., Ltd. (健康元藥業集團股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 600380)
“Latest Practicable Date”	March 17, 2026, being the latest practicable date for the purpose of ascertaining certain information contained in this annual result announcement prior to its publication
“LE2025”	LE2025 Therapeutics AG, an affiliate of Windward Bio Group AG
“Listing”	the listing of our H Shares on the Main Board
“Listing Date”	March 20, 2024, on which dealings in our H Shares first commence on the Main Board

“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended or supplemented or otherwise modified from time to time
“Macau”	the Special Administrative Region of Macau of the PRC
“MAH”	the marketing authorization holder
“Main Board”	the stock exchange (excluding the option market) operated by the Stock Exchange which is independent from and operated in parallel with the Growth Enterprise Market of the Stock Exchange
“Model Code”	the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 to the Listing Rules, as amended, supplemented or otherwise modified from time to time
“monoclonal antibody” or “mAb”	antibody generated by identical immune cells that are all clones of the same parent cell
“Mr. Qiu”	Mr. Qiu Jiwan (裘霽宛), our founder, executive Director, chairman of our Board, our general manager, and one of our Controlling Shareholders
“NDA”	new drug application
“Optional Right”	an exclusive optional right granted by the Company to Zhongmei Huadong to promote the Oturkibart in the Authorized Territory and in the Authorized Fields
“Phase I clinical trial”	study in which a drug is introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, an early indication of its effectiveness. Phase I clinical trial can be further divided into the Phase Ia clinical trial, which is often a single ascending dose study, and the Phase Ib clinical trial, which is often a multiple ascending dose study
“Phase II clinical trial”	study in which a drug is administered to a limited patient population to identify possible adverse effects and safety risks, preliminarily evaluate the efficacy of the product for specific targeted diseases and determine dosage tolerance and optimal dosage
“Phase III clinical trial”	study in which a drug is administered to an expanded patient population generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval and to provide adequate information for the labeling of the product

“Prospectus”	the prospectus issued by our Company on March 12, 2024 in relation to our Global Offering and Listing
“prurigo nodularis” or “PN”	a chronic skin disorder characterized by the presence of hard and extremely itchy bumps known as nodules, which tend to be found in easy-to-scratch areas, such as the arms, legs, the upper back and abdomen
“psoriasis” or “Ps”	a skin disease associated with dysregulation of the immune systems that causes a rash with itchy and scaly patches, most commonly on the knees, elbows, trunk and scalp
“QX005N Agreement”	the Cooperation Agreement dated July 19, 2024 entered into by the Company and Zhongmei Huadong for joint development and commercialization of the Oturkibart
“receptor”	a region of tissue, or a molecule in a cell membrane, which responds specifically to a particular signal, that is any of a neurotransmitter, hormone, antigen or other substance
“Renminbi” or “RMB”	the lawful currency of the PRC
“Reporting Period”	the year ended December 31, 2025
“Roche”	F. Hoffmann-La Roche Ltd, one of the first industrial manufacturers of branded medicines, which has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics
“Saifu Juli”	Taizhou Saifu Juli Biomedical Co., Ltd.* (泰州市賽孚聚力生物醫藥有限公司), a company established in the PRC with limited liability on July 6, 2018 and a direct wholly owned subsidiary of our Company
“Shanghai Quanyou”	Shanghai Quanyou Fanyue Investment Management Partnership (Limited Partnership)* (上海荃友凡悅投資管理合夥企業(有限合夥)), a limited partnership established in the PRC on November 2, 2015 and one of our Controlling Shareholders, which is owned as to approximately 45.71% by Mr. Qiu as its general partner, 8.57% by Ms. Xu Qiu (許秋), the spouse of Mr. Qiu, as one of its limited partners, and 45.71% by three Independent Third Parties as its other limited partners
“Share(s)”	ordinary share(s) with par value RMB1.00 each in the share capital of the Company
“Shareholder(s)”	holder(s) of our Share(s)
“State Council”	the State Council of the PRC (中華人民共和國國務院)

“Stock Exchange”	The Stock Exchange of Hong Kong Limited, a wholly owned subsidiary of Hong Kong Exchange and Clearing Limited
“subsidiary(ies)”	has the meaning ascribed to it under the Listing Rules
“substantial shareholder(s)”	has the meaning ascribed to it under the Listing Rules
“Supervisor(s)”	the supervisor(s) of our Company
“TNF”	tumor necrosis factor, a group of cell signaling proteins (cytokines) that regulate immune cells and mediate the inflammatory responses
“TNF- α ”	a prominent member of the TNF family and one of the cytokines that make up the acute phase reaction, a series of physiological process occurring soon after the onset of inflammatory processes
“TSLP”	thymic stromal lymphopoietin, a protein belonging to the cytokine family, which plays an important role in the maturation of T cell populations through activation of antigen presenting cells (APCs)
“type 2 inflammation”	a specific type of immune response pattern driven by certain type 2 immune cells, which produce the type 2 cytokines (including IL-4, IL-5 and IL-13) and other inflammatory mediators. Diseases that can be caused by dysregulated type 2 inflammation include atopic dermatitis, asthma and chronic rhinosinusitis, etc.
“Unlisted Share(s)”	ordinary Share(s) issued by our Company with a nominal value of RMB1.00 each which is/are not listed on any stock exchange
“urticaria”	a type of skin disease characterized by itchy swelling on the skin surface
“U.S.” or “United States”	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
“U.S. dollar(s)” or “US\$”	United States dollar(s), the lawful currency of the United States
“Windward Bio”	Windward Bio Group AG, a clinical-stage biotechnology company with deep discovery, development, and commercialization expertise committed to transforming the treatment of people living with advanced immunological conditions

“Xinfu Quanxin”	Taizhou Xinfu Quanxin Enterprise Management Partnership (Limited Partnership)* (泰州信孚全心企業管理合夥企業(有限合夥)), a limited partnership established in the PRC on February 27, 2023, which is owned as to approximately 0.56% by Mr. Wu Yiliang, our executive Director and general manager of Cellularforce as its general partner and approximately 99.44% by 27 employees of our Group as its limited partners, and is one of our employee share incentive platforms
“Xinfu Tongxin”	Taizhou Xinfu Tongxin Enterprise Management Partnership (Limited Partnership)* (泰州信孚同心企業管理合夥企業(有限合夥)), a limited partnership established in the PRC on August 19, 2021, which is owned as to approximately 9.52% by Mr. Qiu as its general partner, approximately 11.38% by Xinfu Quanxin as one of its limited partners and approximately 79.09% by 35 employees of our Group as its limited partners, and is one of our employee share incentive platforms and one of our Controlling Shareholders
“Zhongmei Huadong”	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.* (杭州中美華東製藥有限公司), a company established in the PRC with limited liability on December 31, 1992 and one of our Pre-IPO Investors

ACRONYMS

“CDE”	Center for Drug Evaluation (國家藥品監督管理局藥品審評中心), a division of the NMPA responsible for acceptance and technical review of applications for drug clinical trials and drug marketing authorization
“cGMP”	current good manufacturing practice, regulations and procedures that provide for proper design, monitoring, and control of manufacturing processes and facilities
“CMC”	the chemistry, manufacturing and controls processes in the development, licensure, manufacturing and ongoing marketing of pharmaceutical products
“FDA”	the United States Food and Drug Administration
“FPI”	First Patient In
“IASB”	International Accounting Standards Board
“IFRS”	the International Financial Reporting Standards, which as collective term includes all applicable individual International Financial Reporting Standards, International Accounting Standards and Interpretations issued by the IASB
“IND”	Investigational New Drug
“LPI”	Last Patient In
“NMPA”	the National Medical Products Administration of the PRC (國家藥品監督管理局) and its predecessor, the China Food and Drug Administration (國家食品藥品監督管理總局)
“SFO”	the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong, as amended, supplemented or otherwise modified from time to time

By Order of the Board
Qyuns Therapeutics Co., Ltd.
Mr. Qiu Jiwan

Chairman of the Board and Executive Director

Hong Kong, March 27, 2026

As of the date of this announcement, the Board comprises Mr. Qiu Jiwan as chairman and executive Director, Mr. Wu Yiliang and Mr. Lin Weidong as executive Directors, Mr. Yu Xi and Mr. Wu Zhiqiang as non-executive Directors, and Mr. Fung Che Wai, Anthony, Dr. Zou Zhongmei and Dr. Ling Jianqun as independent non-executive Directors.

* For identification purposes only